Evidence map›Paper›PMID 35423835›Full record

ArticleRSC advances2021

Synthesis and characterization of new fluorescent boro-β-carboline dyes.

Dénes Szepesi Kovács, Imre Hajdu, Gergely Mészáros, Lucia Wittner, Domokos Meszéna, Estilla Zsófia Tóth, Zita Hegedűs, Ivan Ranđelović, József Tóvári, Tímea Szabó and 4 more

Abstract read
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. β-Carboline Alkaloids From the Deep-Sea FungusFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dénes Szepesi KovácsResearch Centre for Natural Sciences, Medicinal Chemistry Research Group POB 286 1519 Budapest Hungary abranyi-balogh.peter@ttk.hu keseru.gyorgy@ttk.hu +36-13826961.
Imre HajduResearch Centre for Natural Sciences, Medicinal Chemistry Research Group POB 286 1519 Budapest Hungary abranyi-balogh.peter@ttk.hu keseru.gyorgy@ttk.hu +36-13826961.
Gergely MészárosResearch Centre for Natural Sciences, Comparative Psychophysiology Research Group POB 286 1519 Budapest Hungary.
Lucia WittnerResearch Centre for Natural Sciences, Comparative Psychophysiology Research Group POB 286 1519 Budapest Hungary.ORCID https://orcid.org/0000-0001-6800-0953
Domokos MeszénaResearch Centre for Natural Sciences, Comparative Psychophysiology Research Group POB 286 1519 Budapest Hungary.ORCID https://orcid.org/0000-0003-4042-2542
Estilla Zsófia TóthResearch Centre for Natural Sciences, Comparative Psychophysiology Research Group POB 286 1519 Budapest Hungary.ORCID https://orcid.org/0000-0003-4732-5796
Zita HegedűsNational Institute of Oncology, Department of Experimental Pharmacology POB 21 1525 Budapest Hungary.
Ivan RanđelovićNational Institute of Oncology, Department of Experimental Pharmacology POB 21 1525 Budapest Hungary.
József TóváriNational Institute of Oncology, Department of Experimental Pharmacology POB 21 1525 Budapest Hungary.
Tímea SzabóEgis Pharmaceuticals Plc., Directorate of Drug Substance Development POB 100 1475 Budapest Hungary.ORCID https://orcid.org/0000-0003-0700-4680
Bence SzilágyiDepartment of Organic Chemistry and Technology, Budapest University of Technology and Economics 1521 Budapest Hungary.
Mátyás MilenEgis Pharmaceuticals Plc., Directorate of Drug Substance Development POB 100 1475 Budapest Hungary.ORCID https://orcid.org/0000-0002-3538-8872
György Miklós KeserűResearch Centre for Natural Sciences, Medicinal Chemistry Research Group POB 286 1519 Budapest Hungary abranyi-balogh.peter@ttk.hu keseru.gyorgy@ttk.hu +36-13826961.ORCID https://orcid.org/0000-0003-1039-7809
Péter Ábrányi-BaloghResearch Centre for Natural Sciences, Medicinal Chemistry Research Group POB 286 1519 Budapest Hungary abranyi-balogh.peter@ttk.hu keseru.gyorgy@ttk.hu +36-13826961.ORCID https://orcid.org/0000-0002-9284-5160

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first representatives of the new fluorescent boro-β-carboline family were synthesized by the insertion of the difluoroboranyl group into the oxaza or diaza core. The resulting compounds showed good photophysical properties with fine Stokes-shifts in the range of 38-85 nm with blue and green emission. The energetics of the excitation states and molecular orbitals of two members were investigated by quantum chemical computations suggesting effects for the improved properties of diazaborinino-carbolines over oxazaborolo-carbolines. These properties nominated this chemotype as a new fluorophore for the development of fluorescent probes. As an example, diazaborinino-carbolines were used for the specific labeling of anti-Her2 antibody trastuzumab. The fluorescent conjugate showed a high fluorophore-antibody ratio and was confirmed as a useful tool for labeling and confocal microscopy imaging of tumour cells

Identifiers

PMID35423835
PMCPMC8697281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.